AU2015259337A1 - Methods and compositions of dasotraline for treatment of ADHD - Google Patents

Methods and compositions of dasotraline for treatment of ADHD Download PDF

Info

Publication number
AU2015259337A1
AU2015259337A1 AU2015259337A AU2015259337A AU2015259337A1 AU 2015259337 A1 AU2015259337 A1 AU 2015259337A1 AU 2015259337 A AU2015259337 A AU 2015259337A AU 2015259337 A AU2015259337 A AU 2015259337A AU 2015259337 A1 AU2015259337 A1 AU 2015259337A1
Authority
AU
Australia
Prior art keywords
dasotraline
dosage form
adhd
treatment
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015259337A
Other languages
English (en)
Inventor
Kenneth S. Koblan
Antony D. Loebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of AU2015259337A1 publication Critical patent/AU2015259337A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015259337A 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of ADHD Abandoned AU2015259337A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992588P 2014-05-13 2014-05-13
US61/992,588 2014-05-13
PCT/US2015/030342 WO2015175514A1 (en) 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of adhd

Publications (1)

Publication Number Publication Date
AU2015259337A1 true AU2015259337A1 (en) 2016-12-08

Family

ID=54480544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015259337A Abandoned AU2015259337A1 (en) 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of ADHD

Country Status (10)

Country Link
US (1) US20170266133A1 (https=)
EP (1) EP3142999A4 (https=)
JP (1) JP2017515858A (https=)
KR (1) KR20170003677A (https=)
CN (1) CN106660936A (https=)
AU (1) AU2015259337A1 (https=)
CA (1) CA2948829A1 (https=)
IL (1) IL248846A0 (https=)
MX (1) MX2016014780A (https=)
WO (1) WO2015175514A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512057A (ja) * 2018-01-19 2021-05-13 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 経口製剤
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
JP4610336B2 (ja) * 2002-09-16 2011-01-12 セプラコール インク． トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療
NZ600107A (en) * 2009-12-04 2014-10-31 Sunovion Pharmaceuticals Inc Formulations, salts and polymorphs of transnorsertraline and uses thereof
CA2836066A1 (en) * 2011-05-13 2012-11-22 Dainippon Sumitomo Pharma Co., Ltd. Treatment and management of cns disorders

Also Published As

Publication number Publication date
WO2015175514A1 (en) 2015-11-19
US20170266133A1 (en) 2017-09-21
EP3142999A1 (en) 2017-03-22
CA2948829A1 (en) 2015-11-19
IL248846A0 (en) 2017-01-31
JP2017515858A (ja) 2017-06-15
KR20170003677A (ko) 2017-01-09
EP3142999A4 (en) 2017-12-27
MX2016014780A (es) 2017-07-25
CN106660936A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
CA3073996C (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US20070117838A1 (en) Quinine dosage forms and methods of use thereof
JP2005537268A (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
KR20120101456A (ko) 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법
CN110167562A (zh) Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用
JP2023181398A (ja) 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
Paton Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome
US11324732B2 (en) Methods for the treatment of dyskinesia in cerebral palsy
US20170266133A1 (en) Methods and compositions of dasotraline for treatment of adhd
US10076503B2 (en) Dosage of dasotraline and method for treatment of ADHD
JPH1045582A (ja) アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
Silva et al. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder
KR20240027750A (ko) 뇌성 마비로 인한 이상운동증 치료용 발베나진
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
Aleke et al. Orphenadrine-induced psychosis in an older adult: a case report
CN106163514B (zh) 注意缺陷和多动性障碍的预防及治疗剂
Schmidt et al. P. 3. c. 046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia
Willis et al. P. 3. c. 044 Antipsychotic polypharmacy in a community psychiatric clinic
Lipavský P. 1.075 Citalopram in depressed cardiac patients
JP2016517856A (ja) アミノピリジンを使用した、ある種の卒中に関連した感覚運動障害を治療するための方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted